Dosing chart / Growth hormone
CJC-1295 (no DAC) vs Sermorelin
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| CJC-1295 (no DAC) | Sermorelin | |
|---|---|---|
| Status | Not approved | Not approved |
| Also known as | Mod GRF 1-29 | Geref |
| Typical dose | 100 mcg | 200–500 mcg |
| How often | Daily, 1–3 times | Daily, at bedtime |
| Schedule | One to three times daily, often paired with a GHRP or ipamorelin. | Once daily at bedtime. |
| Daily equivalent | 100–300 mcg/day | 200–500 mcg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | 8–12 weeks reported | 3–6 months reported |
| Notes | Short-acting GHRH analog. No completed efficacy trials; doses are community-reported. | Formerly FDA-approved for childhood growth hormone deficiency; the brand was discontinued commercially. Now available only through compounding. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the CJC-1295 (no DAC) and Sermorelin pages.
Advertisement